| Complicated urinary tract infection
Fetroja vs Recarbrio
Side-by-side clinical, coverage, and cost comparison for complicated urinary tract infection.Deep comparison between: Fetroja vs Recarbrio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRecarbrio has a higher rate of injection site reactions vs Fetroja based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Recarbrio but not Fetroja, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fetroja
Recarbrio
At A Glance
IV infusion
Every 8 hours
Cephalosporin antibacterial
IV infusion
Every 6 hours
Carbapenem + beta-lactamase inhibitor
Indications
- Complicated urinary tract infection
- Pyelonephritis
- Hospital acquired pneumonia
- Pneumonia, Ventilator-Associated
- Hospital acquired bacterial pneumonia
- VABP
- Complicated urinary tract infection
- Pyelonephritis
- Complicated intra-abdominal infection
Dosing
Complicated urinary tract infection, Pyelonephritis 2 grams IV infusion over 3 hours every 8 hours in adults with CLcr 60 to 119 mL/min; dose adjusted for CLcr <60 or >=120 mL/min; duration 7 to 14 days.
Hospital acquired pneumonia, Pneumonia, Ventilator-Associated 2 grams IV infusion over 3 hours every 8 hours in adults with CLcr 60 to 119 mL/min; dose adjusted for CLcr <60 or >=120 mL/min; duration 7 to 14 days.
Hospital acquired bacterial pneumonia, VABP, Complicated urinary tract infection, Pyelonephritis, Complicated intra-abdominal infection Adults with CLcr >=90 mL/min: 1.25 g (imipenem 500 mg/cilastatin 500 mg/relebactam 250 mg) IV infusion over 30 minutes every 6 hours for 4-14 days; dose reduction required for CLcr <90 mL/min; pediatric patients (>=2 kg): weight- and age-based dosing of 37.5 mg/kg every 6-8 hours IV.
Contraindications
- Known history of severe hypersensitivity to cefiderocol, other beta-lactam antibacterial drugs, or any other component of FETROJA
- Severe hypersensitivity (e.g., anaphylaxis) to any component of RECARBRIO
Adverse Reactions
Most common (>=2%) Diarrhea, elevations in liver tests, hypokalemia, infusion site reactions, constipation, rash, candidiasis, headache, nausea, vomiting, hypomagnesemia, atrial fibrillation
Serious Increase in all-cause mortality in carbapenem-resistant gram-negative bacterial infections, hypersensitivity reactions, Clostridioides difficile-associated diarrhea, seizures and other central nervous system adverse reactions
Postmarketing Neutropenia, chromaturia
Most common (>=4%) Anemia, diarrhea, AST increased, ALT increased, hypokalemia, hyponatremia, constipation, pyrexia, rash
Serious Hypersensitivity reactions, seizures and other CNS adverse reactions, Clostridioides difficile-associated diarrhea
Pharmacology
Cefiderocol is a cephalosporin antibacterial that functions as a siderophore, using the bacterial iron uptake mechanism to traverse the outer cell membrane and exert bactericidal activity by inhibiting cell wall biosynthesis through binding to penicillin-binding proteins (PBPs).
RECARBRIO combines imipenem (a carbapenem that inhibits bacterial cell wall synthesis by binding PBP 2 and PBP 1B), cilastatin (a renal dehydropeptidase inhibitor that prevents renal metabolism of imipenem), and relebactam (a diazabicyclooctane beta-lactamase inhibitor that protects imipenem from degradation by serine beta-lactamases including KPC, AmpC-type PDC, SHV, TEM, and CTX-M enzymes).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fetroja
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Recarbrio
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Fetroja
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Recarbrio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Fetroja
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Recarbrio
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Fetroja.
No savings programs available for Recarbrio.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FetrojaView full Fetroja profile
RecarbrioView full Recarbrio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.